F-X Danlos retweeted
Great new work by @skopetz See the press release at swog.org/news-events/news/20…
The addition of vemurafenib to irinotecan and cetuximab in metastatic colorectal cancer improved PFS in this randomized phase II trial, @SWOG S1406 fal.cn/3cD08 #crcsm #JCO
F-X Danlos retweeted
Would love to see LIPI (score based on leukocytes, neutrophils and LDH) predictive value for IO efficacy compared to a 4000$ blood based TMB! @JAMAOnc @mezquita_laura
Lung Immune Prognostic Index for Advanced Non–Small Cell Lung Cancer ja.ma/2CVUZkv
F-X Danlos retweeted
Hölzel & Glodde preview Downward & Coelho &co: "RAS and PD-L1: A Masters’ Liaison in Cancer Immune Evasion" authors.elsevier.com/a/1WFH1… Orig paper: authors.elsevier.com/sd/arti…
F-X Danlos retweeted
CTLA4i & PD1i induced colitis have distinct immunological characteristics...different therapeutic management ? academic.oup.com/ecco-jcc/ar…
F-X Danlos retweeted
Congrats 2017 @NobelPrize Laureates Hall, Rosbash, & Young! Read their research published in Cell Press journals cell.com/nobelprize
F-X Danlos retweeted
Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity @jclinicalinvest insight.jci.org/articles/vie…
F-X Danlos retweeted
Inside Blood Commentary: Erdheim-Chester disease: the “targeted” revolution owl.li/L7iK30f9B0P
F-X Danlos retweeted
On the blog: FDA Approves New Molecularly Targeted Therapeutic for Non-Hodgkin Lymphoma. sm.aacr.org/qGfX30feRIl
F-X Danlos retweeted
FDA approves inotuzumab (Besponsa) for adults with B-cell acute lymphoblastic leukemia cancer.gov/news-events/cance… #NCICancerCurrentsBlog
F-X Danlos retweeted
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy @CellCellPress cell.com/cell/fulltext/S0092…
F-X Danlos retweeted
Dendritic cell and antigen dispersal landscapes regulate T cell immunity jem.rupress.org/content/earl…
F-X Danlos retweeted
Compartmentalization of specialized dendritic cells determines the amount of antigen capture after immunization jem.rupress.org/content/earl…
F-X Danlos retweeted
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation owl.li/zwfF30eP0sO
F-X Danlos retweeted
Cancer is frequent cause of ER visits, esp for pneumonia, w/60% admit rate. Opportunity to address prevention. ja.ma/2glsIJK
F-X Danlos retweeted
Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine ejcancer.com/article/S0959-8…
F-X Danlos retweeted
CAR T-cell therapy approved to treat certain children & young adults w/ form of B-cell acute lymphoblastic leukemia go.usa.gov/xRAyJ
F-X Danlos retweeted
29 septembre RDV pour la 95° Journée SMHP Hématologie et Médecine Interne à Paris : Programme et inscription sur drive.google.com/file/d/0B6I…
F-X Danlos retweeted
.@CanerSaygin et al. show a new role for CD55 as a signaling hub for self-renewal in endometrioid tumors jem.rupress.org/content/earl… @CCLRI
F-X Danlos retweeted
Veille biblio FAI²R: Découvrez les articles sélectionnés pour vous en août ! drive.google.com/file/d/0B6I… Pour s'abonner: [email protected]


























